Event Description

Psychedelics have recently become a serious topic of legal reform and intense commercial investment. In the past few years, dozens of cities and states have enacted or proposed legislation to decriminalize or regulate psychedelics like psilocybin, dimethyltryptamine, mescaline, and ibogaine. Meanwhile, billions of dollars are flowing into psychedelic companies that are researching, patenting, and commercializing these substances.  

For attorneys familiar with the U.S. cannabis industry, many of these developments look familiar. State cannabis markets have faced challenges associated with safety, diversity, access, and competition. This panel assembled a group of attorneys with experience in cannabis and psychedelics law to discuss what legislators, regulators, and professionals in the nascent psychedelics industry should learn from the successes and failures of cannabis regulation.  

Panelists

• Welcome: Carmel Shachar, Executive Director, Petrie-Flom Center
• Hadas Alterman, Founding Partner, Plant Medicine Law Group; Founding Board Member, Psychedelic Bar Association
• Ariel Clark, Founding Partner, Clark Howell; Founding Board Member, Psychedelic Bar Association
• Robert Mikos, LaRoche Family Chair in Law, Vanderbilt Law School
• Vincent Sliwoski, Partner, Harris Bricken Sliwoski
• Moderator: Mason Marks, Florida Bar Health Law Section Professor, Florida State University College of Law; Senior Fellow, Project on Psychedelics Law and Regulation (POPLAR), Petrie-Flom Center at Harvard Law School

This event is sponsored by the Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School with support from the Oswald DeN. Cammann Fund at Harvard University.